The big congressional spending deal largely keeps the status quo for the two powerful industries, potentially leaving patients exposed to higher health costs.
Members of both parties argued the companies were not passing enough of the discounts they received along to their clients, and weren't transparent enough in their business practices.
After Congress addressed drug prices, focus shifted to PBMs, but lawmakers couldn't agree on a consensus plan for reforms.
[
add
]
[
|
|
...
]